Abstract | OBJECTIVES: METHODS: A total of 129 patients followed at the French Reference Center for MSA who underwent routine 24-h ambulatory BP monitoring were included. Unified MSA Rating Scale (UMSARS) scores, drug treatments and the occurrence and cause of death were recorded. RESULTS: Seventy patients died during follow-up (2.9 ± 1.8 years), mainly from terminal illness, pulmonary or sudden death. Multivariate Cox regression analysis, after adjustment for gender, disease duration and severity (UMSARS I+II score), showed that increased daytime systolic BP variability, OH severity and OH drug treatment were independently correlated with mortality. OH treatment was associated with the risk of cardiac causes and/or sudden death (p = 0.01). In a fully adjusted model, male gender [(female vs. male) hazard ratio (HR) 0.56, 95% CI 0.34-0.94, p = 0.03], UMSARS I+II score (HR 1.04, 95% CI 1.02-1.06, p < 0.01), systolic BP daytime variability (HR 3.66, 95% CI 1.46-9.17, p < 0.01) and OH treatment (HR: 2.13, 95% CI 1.15-3.94, p = 0.02) predicted mortality. CONCLUSIONS: Increased daytime BP variability and OH treatment were predictive of mortality in patients with MSA, independently from disease severity. Further studies are required to assess if these associations are explained by more severe autonomic dysfunction or if OH treatment exposes per se to a specific risk in this population.
|
Authors | Anne Pavy-Le Traon, Alexandra Foubert-Samier, Fabienne Ory-Magne, Margherita Fabbri, Jean-Michel Senard, Wassilios G Meissner, Olivier Rascol, Jacques Amar |
Journal | European journal of neurology
(Eur J Neurol)
Vol. 29
Issue 4
Pg. 1025-1034
(04 2022)
ISSN: 1468-1331 [Electronic] England |
PMID | 34971021
(Publication Type: Journal Article)
|
Copyright | © 2021 European Academy of Neurology. |
Topics |
- Autonomic Nervous System Diseases
(drug therapy, etiology)
- Blood Pressure
(physiology)
- Blood Pressure Monitoring, Ambulatory
- Female
- Humans
- Hypotension, Orthostatic
(complications, drug therapy)
- Male
- Multiple System Atrophy
(complications, drug therapy)
|